前幾天剛發表的，複星在中國做的臨試一期數據

https://www.nature.com/articles/s41591-021-01330-9

Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study